Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The pharmaceutical company said late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in the risk of the disease progressing or death.

Results from a phase 3 clinical trial published in the New England Journal of Medicine, today (June 2nd) show that patients ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad ...

Results from a Phase III clinical trial published in the New England Journal of Medicine, show that patients with lung cancer ...